MCA stability tool

Check whether tablets and capsules are suitable for a multi-compartment compliance aid (MCA), and build a list to print.

Browse medicines A to Z

A (medicines beginning with A) B (medicines beginning with B) C (medicines beginning with C) D (medicines beginning with D) E (medicines beginning with E) F (medicines beginning with F) G (medicines beginning with G) H (medicines beginning with H) I (medicines beginning with I) K (medicines beginning with K) L (medicines beginning with L) M (medicines beginning with M) N (medicines beginning with N) O (medicines beginning with O) P (medicines beginning with P) Q (medicines beginning with Q) R (medicines beginning with R) S (medicines beginning with S) T (medicines beginning with T) U (medicines beginning with U) V (medicines beginning with V) W (medicines beginning with W) X (medicines beginning with X) Y (medicines beginning with Y) Z (medicines beginning with Z)

Medicines beginning with F

Formoterol

Formoterol 6micrograms/dose dry powder inhaler

Unsuitable

Stability notes for Formoterol 6micrograms/dose dry powder inhaler

There are no stability notes for this medicine.

Suppliers (4) of Formoterol 6micrograms/dose dry powder inhaler
Oxis 6 Turbohaler (AstraZeneca UK Ltd)
Oxis 6 Turbohaler (CST Pharma Ltd)
Oxis 6 Turbohaler (Lexon (UK) Ltd)
Oxis 6 Turbohaler (Sigma Pharmaceuticals Plc)

Formoterol 12micrograms/dose dry powder inhaler

Unsuitable

Stability notes for Formoterol 12micrograms/dose dry powder inhaler

There are no stability notes for this medicine.

Suppliers

Oxis 12 Turbohaler (AstraZeneca UK Ltd)
Oxis 12 Turbohaler (CST Pharma Ltd)
Oxis 12 Turbohaler (Sigma Pharmaceuticals Plc)

What the ratings mean

Compatible
Suitable for use. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label.
Use with caution
Suitable with mitigations. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label and supported by limited data.
Incompatible
Medicines under this category are not suitable for use in MCAs.
No stability information
These medicines have not been reviewed by SPS.